Identifying and eliminating the roadblocks to comparative-effectiveness research.

@article{Martin2010IdentifyingAE,
  title={Identifying and eliminating the roadblocks to comparative-effectiveness research.},
  author={Daniel F. Martin and Maureen G. Maguire and Stuart L. Fine},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 2},
  pages={
          105-7
        }
}
Dr. Daniel Martin and colleagues describe their experience with a comparative-effectiveness study that highlights important roadblocks and dramatic changes needed in federal infrastructure for such research to be conducted efficiently. 
View on PubMed
faculty.vet.upenn.edu
40 Citations
Highly Influential Citations
1
Background Citations
14
Methods Citations
2
Results Citations
1

40 Citations

Citation Type

Citation Type

How physicians can drive comparative-effectiveness research: lessons from New Zealand.
Cost-related motivations for conducting research: participants should be informed.
TLDR
Head-to-head clinical trials compare the effectiveness of less expensive treatment options with that of more costly treatments to reduce health care spending while maintaining the quality of care.
NBER WORKING PAPER SERIES THE PRAGMATIST’S GUIDE TO COMPARATIVE EFFECTIVENESS RESEARCH
TLDR
It is argued that effectiveness research can generate some moderating effects on cost growth in healthcare if such research can be used to nudge patients away from less-effective therapies, whether through improved decision making or by encouraging beefed-up copayments for cost-ineffective procedures.
Perspectives on Comparative Effectiveness Research
TLDR
Important issues raised by an increased reliance on CER evidence are highlighted and how they could have an impact on health outcomes research and product development.
The Pragmatist&Apos;S Guide to Comparative Effectiveness Research
  • A. Chandra, A. Jena, J. Skinner
  • Medicine, Political Science
    The journal of economic perspectives : a journal of the American Economic Association
  • 2011
TLDR
It is argued that comparative effectiveness research still holds promise and can prove a useful first step even in the absence of cost information if it provides key estimates of treatment effects.
Japan: An Opportunity to Learn?
The Good, the Bad, and the Ugly: Overview of the Health Reform Law and Its Impact on Health-Care Disparities
TLDR
A kind of road map is put together that hopefully will help one to navigate through the complex waters of the new health-care reform law as it concerns health- Care disparities and racial and ethnic minorities.
Perspective: Second-Class Medicine – Implications of Evidence-Based Medicine for Improving Minority Access to Health Care
TLDR
In theory, the increasingly popular concept of evidence-based medicine suggests a potential tool for both cost containment and the reduction of severe racial and ethnic disparities in health-care delivery, as well as enhancing the capacity of policymakers and physicians to make sound, defensible decisions.
The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
TLDR
The HTA programme should consider the following to maintain and increase its impact: providing targeted support for dissemination, focusing resources when important results are unlikely to be implemented by other stakeholders, particularly when findings challenge vested interests.
The 2010 U.S. health reform legislation: Evaluating the experiment
In the early part of 2010, the United States Congress enacted, and President Barack Obama signed into law, the Patient Protection and Affordable Care Act (PPACA) [18]. This massive (more than a…
...
1
2
3
4
...

References

SHOWING 1-6 OF 6 REFERENCES
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
TLDR
Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Ranibizumab for neovascular age-related macular degeneration.
TLDR
Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Ranibizumab in neovascular age-related macular degeneration
TLDR
There is growing evidence that intravitreal administration of ranibizumab and bevacIZumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.
N Engl J Med
  • N Engl J Med
  • 2006
Report to the President and the Congress